Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 CAD | -0.43% | -5.65% | +36.05% |
05-28 | Organigram Signs Three-Year Supply Agreement With Avida Medical in UK | MT |
05-28 | Organigram to Supply U.K.'s Avida Medical With Dried Cannabis Flower in Three-Year Deal | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.05% | 177M | C | ||
-.--% | 339M | - | - | |
+24.69% | 245M | - | ||
+10.31% | 228M | - | ||
+140.55% | 137M | - | - | |
-28.57% | 121M | - | - | |
+32.61% | 120M | - | ||
-47.02% | 111M | C | ||
-.--% | 87.2M | - | - | |
+150.00% | 75.33M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OGI Stock
- Ratings Organigram Holdings Inc.